君聖泰醫藥-B(02511.HK)完成配售合共5655.5萬股 總籌1.25億港元
格隆匯7月7日丨君聖泰醫藥-B(02511.HK)發佈公吿,配售已於2025年7月7日根據配售協議的條款完成。配售代理已根據配售協議的條款及條件按配售價每股配售股份2.21港元成功向不少於六名獨立承配人配售合共5655.5萬股配售股份。
配售所得款項總額合共約為1.25億港元,而公司將收取的配售所得款項淨額合共約為1.234億港元。公司擬將配售所得款項淨額用於集團管線產品熊去氧膽小檗鹼(HTD1801)的臨牀開發及商業化。HTD1801是公司自主研發、首創的靶向腸-肝系統的抗炎及代謝調節劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.